Skip to main content

Find Clinical Trials

Home
Conditions
Communicable Diseases

Clinical trial condition

Communicable Diseases

Explore clinical trials studying Communicable Diseases. Study availability and eligibility vary by location and protocol.

9,172 public trials 550 recruiting studies

Refine in advanced search Browse all conditions

Communicable Diseases trial results

Completed

Community-Based Peer Facilitator Intervention (Zimbabwe)

NCT02496793

Conditions: Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations: Not specified

View Trial Details

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

NCT02105662

Conditions: Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C, +15 more
Locations: Not specified

View Trial Details

Completed

Evaluating the Feasibility of Point of Care Birth Testing in Eswatini

NCT04206878

Conditions: Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +18 more
Locations: Mbabane Government Hospital, Hlathikhulu Hospital, and Good Shepherd Hospital Mbabane, Eswatini

View Trial Details

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

NCT02105701

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations: Not specified

View Trial Details

Completed

Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

NCT02133131

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Not specified

View Trial Details

Completed

A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

NCT01717326

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Not specified

View Trial Details

Completed

Impact of Point-of-Care EID for HIV-Exposed Infants

NCT03824067

Conditions: Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +17 more
Locations: Elizabeth Glaser Pediatric AIDS Foundation Nairobi, Kenya

Elizabeth Glaser Pediatric AIDS Foundation Harare, Zimbabwe

View Trial Details

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

NCT01932762

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Not specified

View Trial Details

Completed

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

NCT01710501

Conditions: Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C (CHC), +15 more
Locations: Not specified

View Trial Details

Completed

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

NCT04155515

Conditions: Blood-Borne Infections, Chronic Hepatics C Virus (HCV) Genotype 1, Cirrhosis, +15 more
Locations: Beijing Tsinghua Changgung Hospital Beijing, China

View Trial Details